The global Non-Invasive Blood Glucose Monitoring System Market market size was exhibited at USD 22.00 billion in 2022 and is projected to hit around USD 166.05 billion by 2032, growing at a CAGR of 22.4% during the forecast period 2023 to 2032.
Key Takeaways:
Non-Invasive Blood Glucose Monitoring System Market Market Report Scope
Report Coverage |
Details |
Market Size in 2023 |
USD 22.00 Billion |
Market Size by 2032 |
USD 166.05 Billion |
Growth Rate From 2023 to 2032 |
CAGR of 22.4% |
Base Year |
2022 |
Forecast Period |
2023 to 2032 |
Segments Covered |
By Technology,By End User,By Modality,By Distribution Channel |
Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
Key Companies Profiled |
Abbott Laboratories ,Medtronic plc, F. Hoffmann-La Roche Ltd., Ascensia Diabetes Care ,Dexcom, Inc., Sanofi Novo Nordisk ,Insulet Corporation, Ypsomed Holdings, Glysens Incorporated |
Key Market Drivers
Constant monitoring - A continuous monitoring system helps to evaluate the condition of the patient constantly and can be reevaluated for selecting the suitable line of treatment and diet. An increase in the number of diabetes patients which is mostly due to a change in their lifestyles and other environmental factors Will drive the market growth in the coming years period obesity is another reason which leads to diabetes which will in turn increase the need for monitoring devices. The number of deaths that have occurred recently, especially in the United States will lead to the growth of the market during the forecast period.
Easy application - The process of operating these techniques is extremely easy and comfortable which attracts potential consumers. The availability of devices that are easy to use will also help in the growth of the market. Constant research and development in this field will lead to the introduction of better and more efficient devices in the coming years period as many new products are being launched in the market the users of these products can easily access their products.
Key Market Challenges
High cost of technology - The expensive devices which are used for the procedure prove to be a major challenge for the key market players. The lack of disposable income available to the people hampers the growth of the market considerably. The development cost of these devices is high and the reimbursement policy is offered in the market are not favorable due to which the market growth will be hampered in the coming years. The supply of these blood glucose monitoring systems is also affected to a great extent. When it comes to the nations like India and China the use of these devices has increased but the high cost of these devices will hamper the growth of the market in the coming years. An increase in the number of expenses made by the consumers for these devices will put a major strain on the consumers especially when it comes to developing nations. In underdeveloped nations, the high cost of these devices will reduce their penetration and prove to be a challenge to enter these markets.
Key Market Opportunities
Increasing demand for advanced technology - Increasing awareness regarding the available facilities and advanced technologies for monitoring non-invasive blood glucose and controlling it has helped the market of non-invasive blood glucose monitoring systems to show tremendous growth. As many market players are engaged in providing innovative products and the availability of advanced technologies for these products will lead to the growth of the market and provide good opportunities in the coming years.
One of the leading technologies which are being used in this industry is electromagnetism. The availability of these devices in the form of wearable and non-wearable types will also provide good opportunities for the growth of this market.
Regional Insights
On the basis of geography, the huge number of people who are suffering from diabetes and non-invasive blood glucose disorders in the region of North America has proved to be a major factor that has made this region a dominant market and is foreseen to continue in a similar fashion during the future as well. As a result of the developed status of the country these sedentary lifestyle practices have increased to a great extent which results from the huge number of multinational companies would you demand long working hours. Hence the increasing amount of stress and lifestyle disorders have proved to be the causative factors for diabetes and other non-invasive blood glucose-related disorders. The demand for non-invasive blood glucose monitoring systems has seen a tremendous boost in this region which is supported by the high disposable income available to the people.
The next largest market which follows is the region of Europe which comprises a huge client base suffering from diabetes. The rapidly growing awareness regarding the management of diabetes among people has boosted the market size of non-invasive blood glucose monitoring systems. The region of Asia Pacific has emerged as the next sector which has shown considerable growth due to the increasing number of people suffering from diabetes and hence the demand and supply of non-invasive blood glucose monitoring systems have increased.
Recent Developments
Key Market Players
Segments Covered in the Report
By Technology
By End User
By Modality
By Distribution Channel
North America
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Non-Invasive Blood Glucose Monitoring System Market
5.1. COVID-19 Landscape: Non-Invasive Blood Glucose Monitoring System Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Non-Invasive Blood Glucose Monitoring System Market, By Technology
8.1. Non-Invasive Blood Glucose Monitoring System Market, by Technology, 2023-2032
8.1.1. Spectroscopy
8.1.1.1. Market Revenue and Forecast (2021-2032)
8.1.2. Electromagnetic
8.1.2.1. Market Revenue and Forecast (2021-2032)
8.1.3. Microwave
8.1.3.1. Market Revenue and Forecast (2021-2032)
8.1.4. Ultrasonic
8.1.4.1. Market Revenue and Forecast (2021-2032)
8.1.5. Thermal
8.1.5.1. Market Revenue and Forecast (2021-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2032)
Chapter 9. Global Non-Invasive Blood Glucose Monitoring System Market, By End User
9.1. Non-Invasive Blood Glucose Monitoring System Market, by End User, 2023-2032
9.1.1. Others
9.1.1.1. Market Revenue and Forecast (2021-2032)
9.1.2. Homecare
9.1.2.1. Market Revenue and Forecast (2021-2032)
9.1.3. Homecare
9.1.3.1. Market Revenue and Forecast (2021-2032)
Chapter 10. Global Non-Invasive Blood Glucose Monitoring System Market, By Modality
10.1. Non-Invasive Blood Glucose Monitoring System Market, by Modality, 2023-2032
10.1.1. Homecare
10.1.1.1. Market Revenue and Forecast (2021-2032)
10.1.2. Homecare
10.1.2.1. Market Revenue and Forecast (2021-2032)
10.1.3. Invasive
10.1.3.1. Market Revenue and Forecast (2021-2032)
10.1.4. Non-invasive
10.1.4.1. Market Revenue and Forecast (2021-2032)
Chapter 11. Global Non-Invasive Blood Glucose Monitoring System Market, By Distribution Channel
11.1. Non-Invasive Blood Glucose Monitoring System Market, by Distribution Channel, 2023-2032
11.1.1. Retail sales
11.1.1.1. Market Revenue and Forecast (2021-2032)
11.1.2. Institutional sales
11.1.2.1. Market Revenue and Forecast (2021-2032)
Chapter 12. Global Non-Invasive Blood Glucose Monitoring System Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technology (2021-2032)
12.1.2. Market Revenue and Forecast, by End User (2021-2032)
12.1.3. Market Revenue and Forecast, by Modality (2021-2032)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Technology (2021-2032)
12.1.5.2. Market Revenue and Forecast, by End User (2021-2032)
12.1.5.3. Market Revenue and Forecast, by Modality (2021-2032)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Technology (2021-2032)
12.1.6.2. Market Revenue and Forecast, by End User (2021-2032)
12.1.6.3. Market Revenue and Forecast, by Modality (2021-2032)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technology (2021-2032)
12.2.2. Market Revenue and Forecast, by End User (2021-2032)
12.2.3. Market Revenue and Forecast, by Modality (2021-2032)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Technology (2021-2032)
12.2.5.2. Market Revenue and Forecast, by End User (2021-2032)
12.2.5.3. Market Revenue and Forecast, by Modality (2021-2032)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Technology (2021-2032)
12.2.6.2. Market Revenue and Forecast, by End User (2021-2032)
12.2.6.3. Market Revenue and Forecast, by Modality (2021-2032)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Technology (2021-2032)
12.2.7.2. Market Revenue and Forecast, by End User (2021-2032)
12.2.7.3. Market Revenue and Forecast, by Modality (2021-2032)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Technology (2021-2032)
12.2.8.2. Market Revenue and Forecast, by End User (2021-2032)
12.2.8.3. Market Revenue and Forecast, by Modality (2021-2032)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technology (2021-2032)
12.3.2. Market Revenue and Forecast, by End User (2021-2032)
12.3.3. Market Revenue and Forecast, by Modality (2021-2032)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Technology (2021-2032)
12.3.5.2. Market Revenue and Forecast, by End User (2021-2032)
12.3.5.3. Market Revenue and Forecast, by Modality (2021-2032)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Technology (2021-2032)
12.3.6.2. Market Revenue and Forecast, by End User (2021-2032)
12.3.6.3. Market Revenue and Forecast, by Modality (2021-2032)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Technology (2021-2032)
12.3.7.2. Market Revenue and Forecast, by End User (2021-2032)
12.3.7.3. Market Revenue and Forecast, by Modality (2021-2032)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Technology (2021-2032)
12.3.8.2. Market Revenue and Forecast, by End User (2021-2032)
12.3.8.3. Market Revenue and Forecast, by Modality (2021-2032)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technology (2021-2032)
12.4.2. Market Revenue and Forecast, by End User (2021-2032)
12.4.3. Market Revenue and Forecast, by Modality (2021-2032)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Technology (2021-2032)
12.4.5.2. Market Revenue and Forecast, by End User (2021-2032)
12.4.5.3. Market Revenue and Forecast, by Modality (2021-2032)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Technology (2021-2032)
12.4.6.2. Market Revenue and Forecast, by End User (2021-2032)
12.4.6.3. Market Revenue and Forecast, by Modality (2021-2032)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Technology (2021-2032)
12.4.7.2. Market Revenue and Forecast, by End User (2021-2032)
12.4.7.3. Market Revenue and Forecast, by Modality (2021-2032)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Technology (2021-2032)
12.4.8.2. Market Revenue and Forecast, by End User (2021-2032)
12.4.8.3. Market Revenue and Forecast, by Modality (2021-2032)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technology (2021-2032)
12.5.2. Market Revenue and Forecast, by End User (2021-2032)
12.5.3. Market Revenue and Forecast, by Modality (2021-2032)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Technology (2021-2032)
12.5.5.2. Market Revenue and Forecast, by End User (2021-2032)
12.5.5.3. Market Revenue and Forecast, by Modality (2021-2032)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Technology (2021-2032)
12.5.6.2. Market Revenue and Forecast, by End User (2021-2032)
12.5.6.3. Market Revenue and Forecast, by Modality (2021-2032)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)
Chapter 13. Company Profiles
13.1. Abbott Laboratories
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Medtronic plc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. F. Hoffmann-La Roche Ltd.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Ascensia Diabetes Care
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Dexcom, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Sanofi Novo Nordisk
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Abbott
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Ypsomed Holdings
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Glysens Incorporated
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms